{"nctId":"NCT03406104","briefTitle":"RESCUE and REVERSE Long-term Follow-up","startDateStruct":{"date":"2018-01-09","type":"ACTUAL"},"conditions":["Leber Hereditary Optic Neuropathy"],"count":62,"armGroups":[{"label":"GS010-treated Eyes","type":"EXPERIMENTAL","interventionNames":["Genetic: GS010"]},{"label":"Sham-treated Eyes","type":"SHAM_COMPARATOR","interventionNames":["Other: Sham Intravitreal Injection"]}],"interventions":[{"name":"GS010","otherNames":["Lenadogene Nolparvovec"]},{"name":"Sham Intravitreal Injection","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Subject was treated with GS010 IVT injection in either of the RESCUE or REVERSE Phase III clinical studies\n* Subject of legal consent age has provided informed consent; subjects that are not of legal consent age have undergone their country-approved clinical trial enrollment consent process\n\nExclusion Criteria\n\n* Subject is unwilling or unable to comply with the protocol requirements\n* Subject has any medical or psychological condition that, in the opinion of the Investigator, may compromise his or her safe participation in the study\n* Subject is taking or intending to take idebenone during the long-term follow-up study period","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Adverse Events (AEs)","description":"Number of Eyes with Ocular Adverse events related to study treatment or study procedures as judged by the investigator reported from year 2 to year 5 post treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Visual Acuity","description":"Change from Nadir to 5 Years post-treatment, Assessed at Baseline in RESCUE and REVERSE studies to year 5 post-treatment, expressed in LogMAR.\n\nOn chart visual acuity: Visual acuity inferior or equal to LogMAR +1.6 Off chart visual acuity: Visual acuity superior to LogMar +1.7\n\nNormal vision LogMar: 0 and less than 0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.46"},{"groupId":"OG001","value":"-0.39","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Responder Analysis: Clinically Relevant Recovery","description":"CRR clinically relevant recovery from Nadir defined as i/ for eyes on chart at Nadir, an improvement of at least -0.2 LogMar from Nadir and ii/ for eyes off chart at Nadir eyes that became on chart.\n\nOff chart visual acuity expressed in LogMar: more than +1.7 On chart visual acuity expressed in LogMar: less than 1.6 Normal vision LogMar: 0 and less than 0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Eyes on Chart","description":"Definition: Visual acuity inferior or equal to LogMAR +1.6 at 5 Years post treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":62},"commonTop":["Cataract","Gamma-Glutamyltransferase Increased","Intraocular Pressure Increased","Covid-19"]}}}